Gallant - Shark Tank Update

Revolutionary pet healthcare took center stage when serial entrepreneur Aaron Hirschhorn leveraged his successful background founding Dog Vacay and personal experience with stem cell therapy to create Gallant, a pioneering service that would make regenerative medicine accessible to beloved pets worldwide. Hirschhorn's inspiration emerged from his own chronic back pain being successfully treated with stem cell therapy, combined with watching his dog suffer from arthritis and recognizing that the same breakthrough medical technology could transform veterinary care for millions of pet families.

Gallant's innovative process partnered with veterinary offices to collect stem cells during routine spay and neuter procedures, utilizing reproductive organs that would otherwise be discarded to extract and cryogenically preserve valuable stem cells in FDA-approved facilities for future therapeutic use. The business model featured lifetime storage for $595 or annual plans at $95 monthly, with treatment costs around $300 through participating veterinarians, while the company's four patents provided competitive protection and veterinary partners earned $100 for each kit processed.

Having already raised $11 million in pre-Shark Tank funding and burning $400,000 monthly to establish their stem cell division, Hirschhorn sought $500,000 for just 2% equity, reflecting the company's $25 million valuation and ambitious vision to revolutionize pet healthcare through cutting-edge regenerative medicine. The compelling pitch featured puppies and dramatic demonstrations about age-related diseases affecting pets, while Hirschhorn's proven entrepreneurial track record and scientific backing from university partnerships and professional athletes provided credibility for their breakthrough approach to extending pet lifespans and improving quality of life.

Lori Greiner and guest shark Anne Wojcicki partnered to secure the deal for $500,000 for 5% equity after recognizing Gallant's long-term potential in the rapidly growing pet healthcare market, despite initial concerns about acquisition costs and pricing strategy that Anne recommended adjusting upward based on her 23andMe experience. The partnership proved transformational as the company implemented Anne's pricing advice by increasing lifetime plans from $595 to $890 while adding services for cats and horses, demonstrating the value of experienced investor guidance in scaling innovative healthcare businesses.

Tragically, Aaron Hirschhorn died in a boating accident in March 2021, creating uncertainty about the company's future leadership, but the strong management team and board of veterinarians successfully maintained operations while honoring his vision of making stem cell therapy accessible to pet families worldwide. Gallant continued expanding their services and raising additional funding, completing a $15 million Series A round in January 2024 to pursue FDA approval for stem cell therapies with expectations of commercialization beginning in 2025, while maintaining consistent growth in their storage and collection services.

We found that Gallant has achieved impressive success with annual revenue reaching $5 million as of 2023 and a current valuation of $20 million, serving thousands of pet families who have discovered that investing in their pets' future health through stem cell banking provides peace of mind and potential life-saving treatment options, proving that innovative healthcare businesses can build sustainable value while making meaningful differences in the lives of beloved animal companions and their devoted families.